Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use

REiNS International Collaboration

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: Because clinically validated biomarkers for neurofibromatosis 1 (NF1) and neurofibromatosis 2 (NF2) have not been identified, we aimed to determine whether genotype-phenotype correlations are useful in clinical trials in NF1 and NF2. METHODS: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Biomarker Group first performed a systematic literature search and reviewed existing data on genetic biomarkers in NF1 and NF2 and in in malignant peripheral nerve sheath tumors. The group then met during a series of consensus meetings to develop a joint report. RESULTS: We found that in NF2, the genetic severity score is clearly of potential clinical use. In NF1, despite over 3,000 constitutional variants having been described in the NF1 gene, only 4 actionable genotype-phenotype correlations exist. The diagnosis and treatment decision of these tumors should ideally include histopathology and compilation of some of the genetic markers. CONCLUSION: We summarized emerging clinical use of genotype-phenotype correlations in neurofibromatosis.

Original languageEnglish (US)
Pages (from-to)S91-S98
JournalNeurology
Volume97
Issue number7
DOIs
StatePublished - Aug 17 2021

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use'. Together they form a unique fingerprint.

Cite this